The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

Waterdrop Inc. has been included in Harvard Business school’s (HBS) Case Collection. Inducted as a business innovation case, ...

Studies presented at the Society of Neurointerventional Surgery’s show links between GLP-1s and the prevention of strokes and ...

Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.

Dr. Ben Zeskind, CEO of Immuneering, discusses the new approach his company is taking to oncology.

The newly approved prefilled syringe version of Shingrix is expected to simplify administration and supports efforts to ...

Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib ...

Health services company Humana announced its first Humana Cognitive Games. 1 The event is designed to give older adults both ...

Priority review was based on results from the Phase IIb SunRISe-1 trial, which showed that patients treated with TAR-200 for ...

Pharmaceutical Executive recently spoke with RheumaGen CEO Richard Freed about his career and the work the biotech is doing ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...